{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-122215","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2024-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.295170+00:00","generated_at":"2026-06-03T05:34:32.812899+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Stoke Therapeutics names Thomas Leggett CFO; Stephen Tulipano resigns","bullets":["Thomas Leggett appointed CFO effective May 7, 2024; previously CFO at Affinia Therapeutics and Black Diamond Therapeutics.","Leggett receives $475,000 base salary, 40% bonus target, and option for 396,200 shares vesting over 4 years.","Current CFO Stephen Tulipano resigns effective May 7; will serve as advisor through Dec 31, 2024.","Tulipano retains equity vesting during transition period and up to $15,000 in outplacement services.","Leggett holds B.A. from Columbia and M.B.A. from Wharton; also board member at Clover Biopharmaceuticals."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-122215","json":"https://secwatch.observer/filing/0001193125-24-122215.json","markdown":"https://secwatch.observer/filing/0001193125-24-122215.md","text":"https://secwatch.observer/filing/0001193125-24-122215.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000119312524122215/0001193125-24-122215-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000119312524122215/d810575d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T05:34:32.812899+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d376e91b4","claim":"Thomas Leggett was appointed as Chief Financial Officer at Stoke Therapeutics, Inc..","evidence_excerpt":"appointed Thomas Leggett as the Chief Financial Officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1623526/000119312524122215/0001193125-24-122215-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"53b77f09c6","claim":"Stephen Tulipano resigned as Chief Financial Officer at Stoke Therapeutics, Inc..","evidence_excerpt":"Resignation of Chief Financial Officer Effective as of the Appointment Date, the Company’s current Chief Financial Off","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1623526/000119312524122215/0001193125-24-122215-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}